Holen Sie sich die Stockscreener-App
234.03
4.26%
9.56
Handel nachbörslich:
235.20
1.17
+0.50%
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
17.68%
1,290.95
|
1,097.03 | 1,249.03 | 773.69 | 594.19 |
| Cost Of Revenue |
11.41%
298.26
|
267.72 | 197.23 | 142.03 | 70.18 |
Selling, General, and Administrative
|
347.92
|
- | - | - | - |
| Costs And Expenses |
9.76%
1,059.51
|
965.32 | 881.04 | 789.89 | 576.11 |
| Operating Income/Loss |
75.71%
231.44
|
131.72 | 367.98 | -16.20 | 18.08 |
| Nonoperating Income/Loss |
17.99%
-53.63
|
-45.46 | -129.01 | -19.16 | -59.67 |
| Income/Loss From Continuing Operations Before Tax |
106.13%
177.81
|
86.26 | 238.97 | -35.36 | -41.60 |
| Income Tax Expense/Benefit |
152.65%
13.31
|
-25.28 | -12.12 | 30.92 | 15.88 |
| Net Income/Loss |
47.47%
164.49
|
111.54 | 251.08 | -66.28 | -57.48 |
| Basic Average Shares |
32,172%
133.61
|
0.414 | 131.45 | 130.63 | 129.68 |
| Diluted Average Shares |
25,603%
138.28
|
0.538 | 137.35 | 130.63 | 129.68 |
| Basic Earnings Per Share |
46.43%
1.23
|
0.84 | 1.91 | -0.51 | -0.44 |
| Diluted Earnings Per Share |
47.56%
1.21
|
0.82 | 1.84 | -0.51 | -0.44 |
1.07%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):